Denmark’s Breye Therapeutics raises €67.5 million to advance oral therapies for early treatment of retinal diseases

What happened

Breye Therapeutics (Breye), a Danish clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, has closed an oversubscribed €67.5 million Series A (an early stage of company funding) financing round. The round was co-led by new investor Mission BioCapital and existing investor Novo Holdings, with participation from existing investor Sound Bioventures and additional new investors, including the […] The post Denmark’s Breye Therapeutics raises €67.5 million to advance oral therapies for early treatment of retinal diseases appeared first on EU-Startups .

The round was co-led by new investor Mission BioCapital and existing investor Novo Holdings, with participation from existing investor Sound Bioventures and additional new investors, including the Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures and Pappas Capital. Breye was founded in 2019 and emerged from stealth in November 2022 after closing a €4 million Seed round led by Novo Holdings and Sound Bioventures.

and industry veteran with more than 20 years of R&D, regulatory, and commercial experience in Europe and the US, leads the company. It is developing a pipeline of oral therapies for eye diseases, such as intermediate age-related macular degeneration and glaucoma.

According to the company, diabetic retinopathy is a leading cause of vision loss among working-age adults, affecting about 130 million people worldwide today. It opines that this unmet medical need, coupled with a growing patient population, highlights the substantial market opportunity for danegaptide.